Nurix Therapeutics, Inc.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is dedicated to writing medicine's next chapter by using targeted protein degradation to outmatch disease. Their mission is to establish degrader-based medicines at the forefront of patient care, providing safer, deeper, and more durable responses for sustained disease control.

Products & Services

Degraders:Designed to eliminate disease-causing proteins by harnessing the cell's natural protein degradation machinery.

Degrader-Antibody Conjugates (DACs):Combine the cell specificity of antibodies with the potency, selectivity, and catalytic activity of degraders for enhanced precision and improved safety.

DEL-AI Discovery Engine:An innovative drug discovery engine powering the protein degradation revolution.

Pipeline:A multi-modal pipeline targeting a broad range of cancers and autoimmune diseases through clinical progress.

Specialties

Targeted Protein Degradation Degrader-Based Medicines DEL-AI Drug Discovery Cancer Treatment Autoimmune Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Offering T: - FT: Equity Offering	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2025-10-27 FD: 2025-10-27	8 investors
2	RT: Equity Offering T: - FT: Equity Offering	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2025-10-22 FD: 2025-10-22	8 investors
3	RT: Public Offering T: - FT: Public Offering	A: 188600000 MR: - FA: approximately $188.6 million FAN: 188600000	D: 2024-04-16 FD: 2024-04-16	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: 125 million FAN: 125000000	D: 2024-04-11 FD: 2024-04-11	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: $175.0 million FAN: 175000000	D: 2024-04-11 FD: 2024-04-11	5 investors

Equity Offering Latest

2025-10-27

$250.0M

8 investors (Pro only)

Equity Offering 2025-10-22

$250.0M

Public Offering 2024-04-16

$188.6M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gwenn M. Hansen

Chief Scientific Officer

A

Arthur T. Sands, M.D., Ph.D.

President, Chief Executive Officer, and Board Director

H

Hans van Houte

Chief Financial Officer

G

Gwenn M. Hansen, Ph.D.

Chief Scientific Officer

C

Christine Ring, Ph.D., J.D.

Chief Legal Officer and Chief Compliance Officer

J

Jason Kantor, Ph.D.

Chief Business Officer

View 17 more team members with Pro

Unlock Full Team Directory

Recent News